浙江医药
(600216)
| 流通市值：119.40亿 | | | 总市值：120.69亿 |
| 流通股本：9.51亿 | | | 总股本：9.62亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,386,186,607.44 | 2,190,864,565.87 | 8,880,602,021.78 | 6,695,297,924.39 |
| 营业收入 | 4,386,186,607.44 | 2,190,864,565.87 | 8,880,602,021.78 | 6,695,297,924.39 |
| 二、营业总成本 | 3,816,258,302.17 | 1,909,389,936.37 | 7,817,212,979.34 | 5,638,082,321.04 |
| 营业成本 | 2,756,910,828.04 | 1,422,853,523.48 | 5,801,863,711.11 | 4,184,975,452.75 |
| 税金及附加 | 41,554,051.16 | 19,243,413.84 | 93,298,471.45 | 65,753,990.71 |
| 销售费用 | 408,736,555.98 | 203,560,021.36 | 894,249,972.43 | 673,694,784.67 |
| 管理费用 | 293,815,593.77 | 132,590,853.04 | 520,888,009.22 | 333,640,913.23 |
| 研发费用 | 246,455,291.12 | 93,812,020.95 | 579,884,528.65 | 473,281,101.15 |
| 财务费用 | 68,785,982.1 | 37,330,103.7 | -72,971,713.52 | -93,263,921.47 |
| 其中:利息费用 | 11,306,885.8 | 4,822,645.88 | 24,870,165.4 | 18,476,829.67 |
| 其中:利息收入 | 20,677,360.67 | 9,247,264.04 | 30,144,729.32 | 21,172,025.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 19,167,315.83 | -653,522.77 | 4,642,415.19 | 21,364,508.75 |
| 加:投资收益 | 29,479,499.11 | 11,200,069.69 | 2,579,951.77 | 5,364,932.36 |
| 资产处置收益 | 18,703.79 | 1,418,473.15 | -81,154.73 | -7,551.84 |
| 资产减值损失(新) | -25,665,359.76 | 1,444,792.29 | -202,120,062.39 | -94,216,487.48 |
| 信用减值损失(新) | -2,947,260.09 | -3,601,664.06 | 5,797,643.04 | 7,131,143.43 |
| 其他收益 | 37,006,433.12 | 15,071,205.73 | 88,722,257.91 | 51,442,194.83 |
| 四、营业利润 | 626,987,637.27 | 306,353,983.53 | 962,930,093.23 | 1,048,294,343.4 |
| 加:营业外收入 | 441,243.77 | 236,054.87 | 4,455,891.04 | 3,963,418.9 |
| 减:营业外支出 | 7,718,234.44 | 138,552.97 | 15,656,496.03 | 5,951,175 |
| 五、利润总额 | 619,710,646.6 | 306,451,485.43 | 951,729,488.24 | 1,046,306,587.3 |
| 减:所得税费用 | 104,147,502.27 | 48,089,942.49 | 191,490,293.24 | 179,574,974.36 |
| 六、净利润 | 515,563,144.33 | 258,361,542.94 | 760,239,195 | 866,731,612.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 515,563,144.33 | 258,361,542.94 | 760,239,195 | 866,731,612.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 606,016,341.66 | 287,012,403.51 | 873,380,229.2 | 933,147,906.73 |
| 少数股东损益 | -90,453,197.33 | -28,650,860.57 | -113,141,034.2 | -66,416,293.79 |
| 扣除非经常损益后的净利润 | 565,344,994.41 | 273,967,327.09 | 834,110,178.67 | 890,908,849.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.63 | 0.3 | 0.91 | 0.97 |
| (二)稀释每股收益 | 0.63 | 0.3 | 0.91 | 0.97 |
| 八、其他综合收益 | -14,630,975.18 | -8,374,276.06 | 17,625,973.28 | 23,198,143.35 |
| 归属于母公司股东的其他综合收益 | -13,934,267.57 | -7,966,428.67 | 16,631,610.47 | 21,758,147.23 |
| 九、综合收益总额 | 500,932,169.15 | 249,987,266.88 | 777,865,168.28 | 889,929,756.29 |
| 归属于母公司股东的综合收益总额 | 592,082,074.09 | 279,045,974.84 | 890,011,839.67 | 954,906,053.96 |
| 归属于少数股东的综合收益总额 | -91,149,904.94 | -29,058,707.96 | -112,146,671.39 | -64,976,297.67 |
| 公告日期 | 2026-08-26 | 2026-04-24 | 2026-04-11 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |